CJC-1295 DAC Made in USA — Third-Party Verified
CJC-1295 DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered with Drug Affinity Complex technology to extend plasma half-life in laboratory models. PX1 Research supplies premium CJC-1295 DAC made in USA, verified through comprehensive lot-specific third-party testing for molecular research applications. Designed exclusively for in vitro and preclinical research, every batch undergoes rigorous HPLC and mass spectrometry analysis to guarantee analytical precision.
Quick answer
CJC-1295 DAC is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered with Drug Affinity Complex technology to extend plasma half-life in laboratory models. PX1 Research supplies premium CJC-1295 DAC made in USA, verified through comprehensive lot-specific third-party testing for molecular research applications. Designed exclusively for in vitro and preclinical research, every batch undergoes rigorous HPLC and mass spectrometry analysis to guarantee analytical precision.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) with Drug Affinity Complex (DAC) is a modified 29-amino-acid peptide derived from the human growth hormone-releasing hormone (GHRH) sequence.
- The primary sequence of [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC is based on Growth Hormone Releasing Factor (1-29), optimized with specific amino acid substitutions to prevent metabolic cleavage.
- In animal models, unmodified GHRH and short-acting peptides display half-lives ranging from 5 to 30 minutes due to rapid renal clearance and enzymatic hydrolysis.
- At the cellular level, [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC binds specifically to the GHRH receptor, a G-protein-coupled receptor (GPCR) localized on the anterior pituitary somatotroph membrane.
Overview of CJC-1295 DAC in Preclinical GH Signaling Research
CJC-1295 with Drug Affinity Complex (DAC) is a modified 29-amino-acid peptide derived from the human growth hormone-releasing hormone (GHRH) sequence. In laboratory models, natural GHRH exhibits a rapid enzymatic breakdown, exhibiting a plasma half-life of only several minutes. To overcome these kinetic limitations in controlled experimental settings, researchers engineered CJC-1295 DAC by attaching a maleimidoproprionic acid (MPA) group to the lysine residue at position 30.
As a potent GHRH analog, CJC-1295 DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By binding covalently to circulating serum albumin following administration in preclinical models, the molecule resists enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). This structural alteration enables scientists to observe continuous, physiological stimulation of pituitary somatotrophs over extended incubation or observation periods, making it an invaluable tool within endocrinology and cellular signaling investigations.
Chemical Structure and the Drug Affinity Complex (DAC) Modification
The primary sequence of CJC-1295 DAC is based on Growth Hormone Releasing Factor (1-29), optimized with specific amino acid substitutions to prevent metabolic cleavage. Substitutions at positions 2 (D-Ala), 8 (Ala), 15 (Ala), and 27 (Leu) significantly enhance stability against trypsin-like and DPP-IV endopeptidases compared to native GHRH(1-29) amide.
The defining characteristic of this compound is the bioconjugate Drug Affinity Complex (DAC) linker. Preclinical studies suggest that upon exposure to endogenous or simulated plasma proteins, the maleimide functional group selectively reacts with the thiol group of Cys34 on serum albumin. This irreversible covalent bond protects the peptide cleavage sites without obstructing its binding affinity for the GHRH receptor (GHRHR). Consequently, researchers utilizing GHRH analogs can evaluate sustained receptor activation kinetics without requiring continuous, complex infusion systems in vitro or in animal models.
Pharmacokinetics: Extended Half-Life vs. Short-Acting GHRH Peptides
In animal models, unmodified GHRH and short-acting peptides display half-lives ranging from 5 to 30 minutes due to rapid renal clearance and enzymatic hydrolysis. Pharmacokinetic profiling of CJC-1295 DAC demonstrates an extended half-life measuring several days in rodent and non-human primate research settings. This unique kinetic profile enables researchers to maintain elevated steady-state concentrations of circulating growth hormone.
Because of this prolonged activity, CJC-1295 DAC provides a distinct secretion dynamic compared to short-acting pulse generators. Rather than inducing isolated, short-duration GH spikes, preclinical models demonstrate elevated baseline GH secretion alongside preserved episodic pulses. Investigating these distinct secretory patterns helps research teams decipher the specific physiological roles of baseline versus pulsatile GH exposure in cellular proliferation, protein translation, and tissue regeneration assays.
Molecular Mechanism: Pituitary Somatotroph Activation and IGF-1 Secretion
At the cellular level, CJC-1295 DAC binds specifically to the GHRH receptor, a G-protein-coupled receptor (GPCR) localized on the anterior pituitary somatotroph membrane. Binding triggers the activation of adenylate cyclase, leading to intracellular accumulation of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA). This signaling cascade initiates transcription of the growth hormone gene and prompts stimulus-coupled exocytosis of stored GH granules.
In vitro data indicate that sustained elevation of circulating GH subsequently activates hepatic growth hormone receptors, stimulating the gene expression and release of Insulin-like Growth Factor 1 (IGF-1). IGF-1 serves as a primary mediator for downstream somatotrophic effects, including enhanced cellular amino acid uptake, collagen synthesis, and satellite cell activation in musculoskeletal research models. Investigating the sustained GHRH-GH-IGF-1 signaling axis offers critical insights into metabolic regulation, bone density modulation, and extracellular matrix repair mechanisms.
Comparative Evaluation: CJC-1295 DAC vs. Related GHRH Peptides
When designing preclinical protocols, selecting the appropriate secretagogue depends directly on the desired pharmacokinetic profile and target receptor dynamics. Researchers evaluating the GHRH class often compare CJC-1295 DAC against non-conjugated counterparts and alternative secretagogues to establish baseline performance metrics.
For example, CJC-1295 No DAC lacks the reactive maleimide linker, resulting in a significantly shorter half-life (approximately 30 minutes) that mimics transient physiological GHRH surges. Similarly, Sermorelin represents a truncated 29-amino-acid fragment of native GHRH with rapid clearance dynamics suitable for acute stimulation assays, while Tesamorelin features a trans-3-hexenoic acid modification tailored for specialized metabolic studies. When paired with ghrelin receptor agonists such as Ipamorelin, CJC-1295 DAC demonstrates synergistic GH release in rodent models, allowing laboratories to explore dual-receptor pathways in somatotroph physiology. Understanding these structural variations ensures laboratories select the precise molecular tool from our comprehensive GH secretagogues catalog.
USA Synthesis and Quality Assurance at PX1 Research
Reliability and reproducibility are essential parameters in scientific inquiry. PX1 Research prioritizes chemical integrity by ensuring that CJC-1295 DAC is synthesized within state-of-the-art, GMP-compliant facilities located in the United States. Domestic manufacturing allows for strict oversight across every step of solid-phase peptide synthesis (SPPS), cleavage, purification, and lyophilization.
By maintaining complete domestic supply chain control, PX1 Research eliminates batch-to-batch variability, heavy metal contamination risks, and degradation associated with prolonged international transit. Every lot of CJC-1295 DAC made in USA is processed under cleanroom conditions, yielding a stable, highly pure lyophilized cake optimized for laboratory research use only.
Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Testing
To ensure uncompromising quality for analytical and bio-assay applications, PX1 Research partners with independent, ISO 17025-accredited laboratories to verify every production batch. We do not rely on internal or unverified claims; every vial is supported by an accessible, lot-specific Certificate of Analysis (COA).
Our standard analytical suite includes high-performance liquid chromatography (HPLC) to confirm peptide purity consistently exceeds 99.0%, and electrospray ionization mass spectrometry (ESI-MS) to verify precise molecular weight and sequence identity. Furthermore, because bacterial endotoxins can confound cell culture viability and induce non-specific inflammatory signaling in preclinical assays, every lot undergoes rigorous chromogenic LAL endotoxin testing to confirm levels remain well below standard laboratory thresholds. Researchers can access detailed testing protocols and sample reports through our dedicated PX1 research library.
Handling, Storage, and Reconstitution Protocols for Laboratory Applications
Lyophilized CJC-1295 DAC is supplied as a sterile, vacuum-sealed powder designed to ensure long-term physical and chemical stability. Upon arrival at the laboratory, unopened vials should be stored in a commercial freezer at -20°C or -80°C, protected from light and moisture. Under these conditions, the un-reconstituted peptide remains stable for extended periods.
For experimental procedures, reconstitution should be performed under a laminar flow hood using sterile, laboratory-grade bacteriostatic water or sterile 0.9% sodium chloride injection solution. Gently stream the solvent down the inner glass wall of the vial rather than splashing directly onto the peptide cake, allowing the material to dissolve naturally without violent agitation. Once reconstituted, liquid solutions must be refrigerated at 2°C to 8°C and utilized within the established stability window for your specific assay protocol. Avoid repeated freeze-thaw cycles to prevent mechanical shear and peptide aggregation.
Sourcing High-Purity CJC-1295 DAC from PX1 Research
PX1 Research is dedicated to supporting universities, biotechnology firms, and independent research institutions with elite-tier scientific compounds. When you purchase CJC-1295 DAC made in USA from PX1, your facility benefits from verified chemical purity, transparent third-party testing, and efficient logistical execution.
Orders are dispatched same-day (Monday through Friday) directly from our strategically located fulfillment hubs in California and Arizona, ensuring minimal transit times and optimal climate control. For large-scale studies, continuous screening projects, or institution-wide procurement, researchers can set up bulk research peptide accounts to streamline supply chain logistics. Trust PX1 Research for the validated analytical standards required to drive rigorous, reproducible scientific discovery.
Frequently Asked Questions
Where is PX1 Research CJC-1295 DAC synthesized?
All CJC-1295 DAC supplied by PX1 Research is synthesized in the USA within GMP-compliant manufacturing facilities to guarantee strict quality control and batch consistency.
How is the purity and identity of CJC-1295 DAC verified?
Every lot undergoes independent, third-party testing at an ISO 17025-accredited laboratory. Testing includes High-Performance Liquid Chromatography (HPLC) for purity and Mass Spectrometry (MS) for exact mass verification.
What is the primary structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a Drug Affinity Complex (maleimidopropionic acid) linker that allows covalent binding to circulating albumin in research models, extending its biological half-life from minutes to several days.
Are Certificates of Analysis (COA) provided with CJC-1295 DAC orders?
Yes. Every shipment is tied to a specific lot number with an accessible COA detailing HPLC purity percentages, mass spectrometry identification, and endotoxin assay results.
What are the endotoxin limits for PX1 Research compounds?
PX1 Research subjects all peptide lots to chromogenic LAL endotoxin testing, ensuring levels meet strict limits suitable for sensitive cell culture and preclinical laboratory applications.
How should lyophilized CJC-1295 DAC be stored upon arrival?
Lyophilized vials should be stored at -20°C or -80°C in a dry, dark environment to preserve chemical integrity prior to reconstitution.
What solvent should be used for laboratory reconstitution?
Reconstitution is typically performed using sterile bacteriostatic water or sterile 0.9% saline solution under aseptic laboratory conditions.
What are the primary research targets evaluated with CJC-1295 DAC?
Preclinical studies utilize CJC-1295 DAC to evaluate GHRH receptor binding, sustained growth hormone dynamics, downstream hepatic IGF-1 transcription, cellular proliferation, and extracellular matrix repair mechanisms.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.